Respiratory Syncytial Virus

Type: Keyphrase

Name: Respiratory Syncytial Virus

First reported 14 hours ago - Updated 14 hours ago - 2 reports

Teva buys respiratory specialist MicroDose Therapeutx

As part of plans to expand its respiratory franchise, Teva Pharmaceutical Industries is to acquire the USA's MicroDose Therapeutx in a deal that could be worth $165 billion.Under the terms of the deal, the Israeli drugmaker will acquire all of privately-held ... [Published Pharma Times - 14 hours ago]

Entities: Teva Pharmaceutical Industries Ltd, Michael Hayden, Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Replication

First reported Jun 18 2013 - Updated Jun 18 2013 - 1 reports

Teva to acquire MicroDose for up to $165 million

MicroDose developing drug to treat respiratory syncytial virusRelated ContentJERUSALEM — Teva Pharmaceutical Industries will spend up to $165 million to buy a company developing a drug to prevent viral respiratory infections.Teva said it would acquire ... [Published Drug Store News - Jun 18 2013]

Entities: Teva Pharmaceutical Industries Ltd, Respiratory Syncytial Virus, Michael Hayden, Respiratory Infections, Drugs

First reported Jun 17 2013 - Updated Jun 18 2013 - 1 reports

University of Helsinki

One step closer to vaccine for common respiratory disease

The RS virus causes flu-like symptoms in healthy adults, but becomes life-threatening in young children and the elderly. The 3-D structure has been now solved by the Sarah Butcher Lab in the University of Helsinki. Credit: Sarah Butcher Lab, University ... [Published Medical Xpress - Jun 17 2013]

Entities: University of Helsinki, Virus, Vaccine

First reported Jun 18 2013 - Updated Jun 18 2013 - 1 reports

RSV structure revealed by cryo-ET [Microbiology]

Human respiratory syncytial virus is a human pathogen that causes severe infection of the respiratory tract. Current information about the structure of the virus and its interaction with host cells is limited. We carried out an electron cryotomographic ... [Published PNAS - Jun 18 2013]

Entities: Microbiology, Protein, Virion, Glycoprotein, Pathogen

First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

Racemic Adrenaline and Inhalation Strategies in Acute Bronchiolitis

Acute bronchiolitis in infants, which frequently leads to hospitalization, and sometimes requires ventilatory support, is occasionally fatal; it is usually viral in origin, with respiratory syncytial virus being the most common cause. The clinical disease ... [Published The New England Journal of Medicine: Pediatrics - Jun 13 2013]

Entities: Bronchiolitis, Inhalation, Respiratory Syncytial Virus

First reported Jun 05 2013 - Updated Jun 05 2013 - 1 reports

MedImmune Inc

Research and Markets: PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/tvlnlj/pharmapoint) has announced the addition of the report to their offering. GlobalData has released its pharma report, PharmaPoint: Pediatric Respiratory Syncytial ... [Published Yahoo! Finance - Jun 05 2013]

Entities: Respiratory Syncytial Virus, Novavax Inc, MedImmune Inc, Market

First reported Jun 04 2013 - Updated Jun 04 2013 - 2 reports

A $22 Billion Industry That Nobody On Wall Street Is Talking About

Suffering from a debilitating condition known as respiratory syncytial virus, the patient lay on the ground wheezing with every tormented breath.It's a horrible yet common viral condition that brings a high fever, a hacking cough, and progressive difficulty ... [Published Money Morning - Jun 04 2013]

Entities: Animal Health, Nutrition, Respiratory Syncytial Virus

First reported Jun 03 2013 - Updated Jun 04 2013 - 2 reports

Now Available: EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US - Epidemiology Forecast to 2022

New Pharmaceuticals market report from GlobalData: "EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US - Epidemiology Forecast to 2022"Boston, MA -- (SBWIRE) -- 06/03/2013 -- EpiCast Report: Pediatric ... [Published SBWire - Jun 03 2013]

Entities: Epidemiology, Respiratory Syncytial Virus, infections, Infection, Congenital

First reported May 29 2013 - Updated May 30 2013 - 3 reports

GlaxoSmithKline acquires Okairos for EUR250m to boost vaccines business

GlaxoSmithKline (GSK) has acquired a Switzerland-based vaccines company, Okairos, for EUR250m in cash to boost its existing vaccine platform technology expertise and to continue developing the next generation of vaccines. Under the terms of the strategic ... [Published Big News Network - May 30 2013]

Entities: Okairos, Vaccine, GlaxoSmithKline plc

First reported May 29 2013 - Updated May 30 2013 - 2 reports

GSK strengthens vaccines business with Okairos buy

GlaxoSmithKline has purchased the Swiss-based vaccine technology company Okairos for 250 million euros in a deal that will bolster the firm’s biologics division.Swiss-based Okairos, a private biotech company, has developed a vaccine platform technology ... [Published Pharma Times - May 30 2013]

Entities: Vaccine, Okairos, Respiratory Syncytial Virus, Malaria, Riccardo Cortese

First reported May 29 2013 - Updated May 29 2013 - 1 reports

Study Data from M.S. Ozdemir et al Provide New Insights into. . .

By a News Reporter-Staff News Editor at Life Science Weekly -- Current study results on Immunology have been published. According to news reporting out of Beerse, Belgium, by NewsRx editors, research stated, "We report here on a new potentiometric biosensing ... [Published Equities.com - May 29 2013]

Entities: Membrane, Beerse (Belgium), Ion

First reported May 23 2013 - Updated May 23 2013 - 1 reports

PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022

(PR Newswire) Reportlinker.com announces that a new market research report is available in its catalogue: PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to... ... [Published Individual.com - May 23 2013]

Entities: Respiratory Syncytial Virus, market analysis, Drugs

Quotes

Michael Hayden, Teva's chief scientific officer, said that the MicroDose platform "is both simple and attractive, and their addition will help us to address the unmet needs of the youngest and oldest patients who have a requirement for a better way of taking the medicines they rely upon"

Teva buys respiratory specialist MicroDose Therapeutx [Published Pharma Times - 14 hours ago]

...platform technology and development programs for the greatest benefit of patients," said Anand V Gumaste, CEO of MicroDose, in a statement. "Teva has a strong and growing franchise in respiratory diseases, with extensive experience in both delivery mechanisms and novel therapeutic modalities."

Teva grabs MicroDose respiratory biz with inhaled delivery platform [Published FiercePharma - 22 hours ago]

"I am thrilled tha tTeva can now count the exciting MicroDose products and technologies amongst our growing respiratory portfolio" Teva chief scientific officer and president for global research and development Michael Hayden said...

Teva to acquire MicroDose for up to $165 million [Published Drug Store News - Jun 18 2013]

"In addition, we observed that the fusion protein on the surface is in two different forms. The fusion protein is responsible for attaching the virus to human cells and invading them. This is an important finding because the fusion protein is the key molecule in developing therapeutic antibodies to the virus. "

One step closer to vaccine for common respiratory disease [Published Medical Xpress - Jun 17 2013]

More Content

sort by: Date \| Relevance
Community-acquired pneumonia in Chile: the clin... [Published British Journal of the Thorax - 8 hours ago]
Teva buys respiratory specialist MicroDose Ther... [Published Pharma Times - 14 hours ago]
Teva buys respiratory specialist MicroDose Ther... [Published Big News Network - 14 hours ago]
Teva grabs MicroDose respiratory biz with inhal... [Published FiercePharma - 22 hours ago]
Teva Pharma breaks M&A silence with bite-sized ... [Published FierceBiotech - Jun 18 2013]
Teva to acquire MicroDose for up to $165 million [Published Drug Store News - Jun 18 2013]
Teva to Acquire MicroDose Therapeutx Zacks [Published Yahoo! Finance - Jun 18 2013]
Teva Pharmaceutical Industries Ltd to acquire M... [Published Individual.com - Jun 18 2013]
Coming Soon: A vaccine for Respiratory Infection [Published Firstpost.com - Jun 18 2013]
Teva Pharmaceutical to take over MicroDose Ther... [Published Pharmaceutical Business Review - Jun 18 2013]
RSV structure revealed by cryo-ET [Microbiology] [Published PNAS - Jun 18 2013]
Evening Business News digest [Published Delaware Online - Jun 18 2013]
One step closer to vaccine for common respirato... [Published Medical Xpress - Jun 17 2013]
Teva Snaps Up MicroDose Therapeutx in Up To $16... [Published Genetic Engineering News - Jun 17 2013]
Teva Pharmaceutical Industries Ltd Strengthens ... [Published Reuters UK - Jun 17 2013]
Teva acquires MicroDose Therapeutx [Published Globes - Jun 17 2013]
TEVA PHARMACEUTICAL INDUSTRIES LIMITED: Teva Ag... [Published 4 Traders - Jun 17 2013]
Teva Strengthens Respiratory Franchise with Acq... [Published BioPortfolio - Jun 17 2013]
Learning at the molecular level [Published Memphis Commercial Appeal - Jun 15 2013]
New Market Report: EpiCast Report: Dermatophyti... [Published SBWire - Jun 14 2013]
Conditional Placing to raise $25.5 million [Published Noodls - Jun 14 2013]
Conditional Placing to raise ?25.5 million [Published Best Invest - Jun 14 2013]
Racemic Adrenaline and Inhalation Strategies in... [Published The New England Journal of Medicine: Pediatrics - Jun 13 2013]
Quidel acquires BioHelix Corp. [Published Drug Discovery News - Jun 12 2013]
Adrenaline No Help for Infant Bronchiolitis (CM... [Published MedPage Today - Jun 12 2013]
Report Published: "Functional (Non Ulcer) Dyspe... [Published SBWire - Jun 12 2013]
When It Comes To Biotech, Diversity Is Key [Published Seeking Alpha - Jun 12 2013]
Biota Initiates Phase 2 Trial of Laninamivir Oc... [Published Scottrade - Jun 11 2013]
Novavax: A Vaccine Company With Large Long-Term... [Published Seeking Alpha - Jun 10 2013]
Intranasal immunization with a helper-dependent... [Published 7thSpace - Jun 09 2013]

sort by: Date \| Relevance
A $22 Billion Industry That Nobody On Wall Stre... [Published EquityJungle - v0.1 - Jun 04 2013] Suffering from a debilitating condition known as respiratory syncytial virus, the patient lay on the ground wheezing with every tormented breath. It's a horrible yet common viral condition that brings a high fever, a hacking cough, and progressive ...
Mackay: Patenting MERS no hindrance to diagnosis [Published H5N1 - May 25 2013] Via his blog Virology Down Under, Dr. Ian Mackay argues that Patenting MERS-CoV: no hindrance to diagnosis at all. Excerpt:This is not the first newly identified virus that researchers at Erasmus, or elsewhere, have patented. They did the same for human ...
Reducing Respiratory Virus in Preemies Lessens ... [Published MedlinePlus Health News - May 08 2013] But preventing respiratory synctial virus comes with a hefty price tagSource: HealthDayRelated MedlinePlus Pages: Premature Babies , Respiratory Syncytial Virus Infections ...
CIDRAP: US labs progress with H7N9 studies as C... [Published H5N1 - May 02 2013] Via CIDRAP, Lisa Schnirring writes: US labs progress with H7N9 studies as CDC urges readiness. Excerpt:As labs in the United States study how the H7N9 virus behaves in humans and animals, state and local health officials should dust off their pandemic ...
Children’s Discovery Institute Awards $2.7 mill... [Published WUSTL Science & Technology News - Apr 22 2013] Understanding and solving the mysteries of tuberculosis and malnutrition, seeking answers that will help develop and improve outcomes for childhood cancers — these are some of the important new research projects under way at the Children’s Discovery ...